BioXcel Therapeutics, Inc. announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO). Mr. Wiley brings a wealth of sales, marketing, and strategy experience across multiple specialty product launches. He joins BioXcel Therapeutics from VYNE Therapeutics, where he served as CCO overseeing all commercial objectives related to the launch of the company's first two approved dermatology products, AMZEEQ® and ZILXI®.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.415 USD | -4.39% | -21.82% | -52.03% |
05-09 | BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.03% | 53.11M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- BTAI Stock
- News BioXcel Therapeutics, Inc.
- BioXcel Therapeutics, Inc. Appoints Matt Wiley as Senior Vice President and Chief Commercial Officer